Navigation Links
Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
Date:10/21/2008

ROCKVILLE, Md., Oct. 20 /PRNewswire/ -- Glycotex, Inc. today announced enrollment of the first patient in a Phase IIb study evaluating the effect of GLYC-101 on wound closure and cosmetic outcomes in cosmetic surgery patients undergoing carbon dioxide laser skin resurfacing on the lower eyelid area.

A previous Phase II Pilot Study, investigating clinical outcomes and safety parameters of GLYC-101 at two doses compared to placebo was completed in April 2008.

The current randomized, double-blind, placebo-controlled clinical study will enroll approximately 48 patients at one clinical trial site in Beverly Hills, California. Patients will be randomized to receive either GLYC-101 0.1% or GLYC-101 1.0% gel on one lower eyelid, and placebo on the other lower eyelid applied topically to the laser-ablated area immediately following the laser procedure and for four consecutive days thereafter. The primary efficacy endpoint of the study is time to wound healing, and the secondary efficacy point is cosmetic outcomes, including scarring. The study will observe the effects of the topical agent over the course of one month following the initial treatment with the investigational compound and placebo.

About GLYC-101

GLYC-101 is intended to stimulate and modulate the natural cascade of wound healing activities of several cell populations. The product candidate is a topical gel to be applied directly on the wound surface. In May 2006, Glycotex completed a Phase II clinical trial of GLYC-101 in Australia, in which GLYC-101 produced a statistically significant rate of wound area reduction versus combined placebo and standard care in patients with chronic venous ulcers. The results provided proof-of concept and dose-ranging information for GLYC-101.

The strategic priorities for GLYC-101 include wound healing following laser ablation, burn wounds, surgical wounds, venous ulcers and diabetic ulcers.

About Glycotex, Inc.

Glycotex, Inc. is a U.S. based development stage biopharmaceutical company focused on discovering and developing therapies intended to accelerate human wound healing and tissue repair across a wide range of human applications. It has licensed from Novogen Limited certain patent rights and know-how to use and exploit its technology in a wide range of wound healing applications. Glycotex, Inc. is an 81 percent owned subsidiary of Novogen Limited. For more information, visit http://www.glycotexinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates, costs and delays in the development and/or FDA approval, or the failure of our products to obtain such approval, uncertainties in clinical trial results, our inability to maintain or enter into, and the risks resulting from, our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, competitive factors, our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business, our inability to operate our business without infringing the patents and proprietary rights of others, general economic conditions, the failure of any products to gain market acceptance, our inability to obtain any additional required financing, technological changes, government regulation, changes in industry practice and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE Glycotex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
2. PURE Bioscience Reports Fourth Quarter and Year End Results
3. Cryo-Cell International, Inc. Reports Third Quarter 2008 Results
4. Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008
5. Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
6. Neptune Technologies & Bioressources Inc. reports first quarter results
7. CardioDynamics Reports Third Quarter 2008 Results, Seventh Consecutive Quarterly Revenue Growth and 15% Year to Date Revenue Increase
8. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. Corgenix Reports Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Francisco, CA (PRWEB) , ... ... ... leader uBiome is opening applications to an early access program for SmartBiome ... of metagenomic deep-sequencing with the simultaneous specific enrichment and detection of hundreds ...
(Date:12/6/2016)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today ... fiscal year ended September 30, 2016. ... , , SQI ... company that develops and commercializes proprietary technologies and products for advanced ... revenues of $1.4 million more than tripling prior years revenue. ...
(Date:12/6/2016)... ... ... Discovering new clues to natural treatments that could allow our bodies to ... And searching for keys to our immune systems by studying parasite-resistant fish. These are ... Edith and Peter O’Donnell Awards by The Academy of Medicine, Engineering and ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... Point Partners ("GPP") portfolio company, today announced it has acquired the assets ... subsidiary of Chiltern International and focuses on clinical trial drug packaging, labeling, ...
Breaking Biology Technology:
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
Breaking Biology News(10 mins):